Open AccessHuman CD34 + cells differentiate into microglia and express recombinant therapeutic protein
Author(s) -
Muriel Asheuer,
Françoise Pflumio,
Sonia Benhamida,
Anne DubartKupperschmitt,
Françoise Fouquet,
Yoshinori Imai,
Patrick Aubourg,
Nathalie Cartier
Publication year - 2004
Publication title -
proceedings of the national academy of sciences of the united states of america
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.011
H-Index - 771
eISSN - 1091-6490
pISSN - 0027-8424
DOI - 10.1073/pnas.0306431101
Subject(s) - microglia , cd34 , bone marrow , stem cell , biology , transplantation , immunology , microbiology and biotechnology , cancer research , medicine , inflammation
In rodents, bone marrow-derived cells enter the brain during adult life. Allogeneic bone marrow transplantation is used to treat genetic CNS diseases, but the fate of human bone marrow and CD34(+) cells within the brain remains to be elucidated. The present study demonstrates that cells derived from human CD34(+) cells, isolated from either cord blood or peripheral blood, migrate into the brain after infusion into nonobese diabetic/severe combined immunodeficient mice. Both types of CD34(+)-derived cells differentiate into perivascular and ramified microglia. The lentiviral transfer of genes into CD34(+) cells before infusion does not modify the differentiation of human CD34(+) cells into microglia, allowing new transgenic proteins to be expressed in these cells. The transplantation of CD34(+) cells could thus be used for the treatment of CNS diseases.